Adequate Selection Of Fluoropyrimidines For Colorectal Cancer

Ninety-four colorectal cancer patients underwent the surgical therapy and the activity of TS and the expression of DPD in their tumor tissue were measured. Their prognosis was compared with the contents of the enzymes and the used fluoropyrimidines. The patients received LV+5-FU and DPD inhibitory fluoropyrimidines (DIF) tended to have better prognosis than the patients receiving other type of fluoropyrimidines. The prognosis of the patients with low TS activity tended to be better than that of high TS patients. However, in the patients receiving LV+5-FU there was no difference between the two groups. The prognosis of the patients with low DPD activity was not influenced by the kinds of fluoropyrimidines. However, the prognosis of the patients receiving DIF was better than that of the patients receiving LV+5-FU (p=0.03). Therefore, the method of drug selection considering the enzymes relating fluoropyrimidines was useful for the adjuvant chemotherapy after the resection of colorectal cancer.